Chen X, et al. - The specific effects of bosentan for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) were assessed via a systemic review and meta-analysis. Efficacy of bosentan was shown, as a treatment option for PAH. Concerning its therapeutic impact in CTEPH, the improvement was noted in certain hemodynamic parameters only. Notably, higher incidence of liver function abnormality was documented in bosentan treatment.